Author: WTN News

IT failures on expensive and high-risk projects in state agencies have gobbled up both newsprint and tax dollars, but not every state IT dollar has been wasted, notes columnist Tom Still. In this edition of Inside Wisconsin, Still toasts one state IT investment that actually...

You've heard of famous “Dream Teams” in basketball (think 1992 Olympics) and in legal circles (think O.J. Simpson), but how about a technology Dream Team of Microsoft's Bill Gates and Apple's Steve Jobs? In this edition of DEMO Letter, Chris Shipley's dreams include a “what...

Citing the need to achieve profitability, Hutchinson Technology, which owns one of the Chippewa Valley's largest manufacturing plants, is cutting back its Eau Claire workforce by 165 workers. Hutchinson manufactures suspension assembly products for disk drives for the computer industry, and sales have slumped...

Perscitus Biosciences will use a $250,000 loan from the Wisconsin Department of Commerce to further develop two promising scientific technologies., including one that selectively protects normal cells from the toxic effects of chemotherapy and radiation therapy. Both technologies have passed early proof-of-concept milestones. ...

NeoClone, a Madison biotechnology company, has landed a $750,000 federal contract to continue its research into a test for ovarian cancer, which is one of the most difficult forms of cancer to detect in its early stages. Ovarian cancer is the fifth leading cause of...

A new benchmarking technique has the potential to save a substantial amount of money in any Sarbanes-Oxley compliance program, but the first step is to have effective IT change management in place. In this edition of Boardroom Perspectives, project management professional Jerry Norton explains why...

In a dramatic one-year rise, Wisconsin surpassed the $100 million level in annual angel capital investments in 2006, according to a new report by NorthStar Economics. Investment experts believe that bodes well for the state's future ability to attract later-stage venture capital and provide technology...

The United States is still a dominant player in global biotech sales, R&D, publicly traded companies, and other parameters, but the rest of the world is catching up. In this edition of Yer Biotech Blues, columnist Michael Rosen outlines this and other findings from the...